Researchers have discovered that a new drug called diranersen may help slow cognitive decline in people with early Alzheimer’s disease by reducing tau protein levels in the brain. This finding marks a significant shift in Alzheimer’s research, which has primarily focused on amyloid plaques, the sticky protein clumps traditionally associated with the disease. The Phase 2 CELIA study, conducted by Biogen and Ionis Pharmaceuticals, involved 416 participants and aimed to assess the effects of diranersen on tau protein, which is believed to play a crucial role in the progression of Alzheimer’s.

This research is important for anyone concerned about aging and cognitive health. The results indicate that lowering tau levels could lead to slower cognitive decline, meaning that individuals may retain their memory and cognitive abilities for longer periods. Specifically, those who received the lowest dose of diranersen showed a notable slowdown in cognitive decline alongside a reduction in tau buildup in the brain. This dual benefit suggests that the drug may not only alleviate symptoms but also address the underlying biological processes of Alzheimer’s.

While the CELIA study did not meet its primary endpoint, the observed reductions in tau biomarkers and the cognitive benefits are promising. The study’s results are still in early stages, and larger trials are needed to confirm these findings and assess long-term safety, especially at higher doses where some serious side effects were noted. However, the interest in tau-targeting therapies like diranersen reflects a broader shift in Alzheimer’s research towards understanding and intervening in the disease earlier.

As research progresses, staying informed about new treatments and maintaining a healthy lifestyle may be beneficial for cognitive health. Engaging in regular physical activity, a balanced diet, and mental exercises can support brain health as you age.

Source: longevity.technology